Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).
![CINRYZE® (C1 esterase inhibitor [human]) Logo](/dist/images/hdr-log3.webp)
![CINRYZE® (C1 esterase inhibitor [human]) Logo](/dist/images/hdr-logo2.webp){kind=logo}
For your patients with
hereditary angioedema (HAE)...
They can
do this.
CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life. CINRYZE has been proven to reduce attack frequency, severity, and the use of acute treatment.1,2
Start with HAE attack prevention
CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life. CINRYZE has been proven to reduce attack frequency, severity, and the use of acute treatment.1,2
Start with HAE attack prevention.
Help your patients embrace preventive treatment
Starting your patients on CINRYZE gives them access to preventive therapy along with resources and support for their journey with HAE.1
Learn about pediatric use
Find out more about the expanded indication of CINRYZE to include patients aged 6 to 11.1
Dosing and Administration
CINRYZE for prevention can be self-administered or administered by a caregiver or healthcare provider.1
OnePath® Product Support
OnePath provides patients and their caregivers with a dedicated Patient Support Manager who can assist with navigating insurance coverage, self-administration training and more.
Request a sales representative
If you'd like to learn more about CINRYZE for your HAE patients, please get in touch.
Reference
- CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.
- Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:6.
